

Cynthia Aranow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2059306/publications.pdf>

Version: 2024-02-01

88
papers

8,131
citations

136885

32
h-index

82499

72
g-index

88
all docs

88
docs citations

88
times ranked

9069
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	1.5	7
2	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.5	42
3	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.5	9
4	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 1822-1828.	1.5	9
5	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	2.2	17
6	Determination of the minimal clinically important difference (MCID) of the physician global assessment (PGA) in SLE. Annals of the Rheumatic Diseases, 2022, 81, 1336-1337.	0.5	2
7	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	1.5	13
8	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	1.5	22
9	Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial. Annals of the Rheumatic Diseases, 2021, 80, 203-208.	0.5	82
10	Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis and Rheumatology, 2021, 73, 121-131.	2.9	117
11	Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology, 2021, 60, 5379-5389.	0.9	11
12	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	0.8	3
13	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	2.9	7
14	The brain in SLE. , 2021, , 231-255.		0
15	Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus. Lupus Science and Medicine, 2021, 8, e000559.	1.1	10
16	1105â€¦Telemedicine in rheumatology: a survey of patient and provider satisfaction with virtual care. , 2021, , .		0
17	1124â€¦Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
18	1107â€¦Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
19	801â€¦Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk. , 2021, , .		0
20	1704â€¦Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
21	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	1.1	97
22	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	2.9	39
23	A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Rheumatology, 2020, 59, 1505-1513.	0.9	3
24	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	1.5	23
25	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	2.9	26
26	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	3.0	27
27	Discrepant Perception of Lupus Disease Activity. Journal of Clinical Rheumatology, 2020, 26, S165-S169.	0.5	13
28	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.5	40
29	Reliability of Visual Analog Scale and Numeric Rating Scale for the Assessment of Disease Activity in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2020, 26, S170-S173.	0.5	5
30	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€¦FI). Arthritis Care and Research, 2020, , .	1.5	9
31	Response to: â€œPhysician global assessment in systemic lupus erythematosus: can we rely on its reliability?â€™ by Chessa et al. Annals of the Rheumatic Diseases, 2020, , annrhumdis-2020-217692.	0.5	0
32	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	2.9	17
33	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacept phase 2b ADDRESS II study. Rheumatology, 2020, 59, 2930-2938.	0.9	33
34	Laboratory investigation results influence Physicianâ€™s Global Assessment (PGA) of disease activity in SLE. Annals of the Rheumatic Diseases, 2020, 79, 787-792.	0.5	20
35	Inhibition of IRF5 hyperactivation protects from lupus onset and severity. Journal of Clinical Investigation, 2020, 130, 6700-6717.	3.9	48
36	Response to: â€œPhsician's global assessment is often useful in SLE, but not always: the case of clinical remissionâ€™ by Zenet al. Annals of the Rheumatic Diseases, 2020, , annrhumdis-2020-217687.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70
38	Metabolic and microstructural alterations in the SLE brain correlate with cognitive impairment. JCI Insight, 2019, 4, .	2.3	52
39	Alterations in Blood-Brain Barrier Permeability in Patients with Systemic Lupus Erythematosus. American Journal of Neuroradiology, 2019, 40, 470-477.	1.2	28
40	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	2.9	25
41	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	0.9	8
42	Dynamic Contrast-Enhanced MRI Reveals Unique Blood-Brain Barrier Permeability Characteristics in the Hippocampus in the Normal Brain. American Journal of Neuroradiology, 2019, 40, 408-411.	1.2	18
43	Reply:. American Journal of Neuroradiology, 2019, 40, E42-E43.	1.2	1
44	178â€“Phase 2 trial of induction therapy with anti-CD20 (Rituximab) followed by maintenance therapy with anti-BAFF (Belimumab) in patients with active lupus nephritis. , 2019, , .		0
45	Effect of vitamin D on serum markers of bone turnover in SLE in a randomised controlled trial. Lupus Science and Medicine, 2019, 6, e000352.	1.1	3
46	209â€“Attainment of low disease activity and remission with ataccept in patients with systemic lupus erythematosus and high disease activity in the phase IIb ADDRESS II study and its long-term extension. , 2019, , .		0
47	<i>Reply:</i>. American Journal of Neuroradiology, 2019, 40, E67-E68.	1.2	0
48	Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance. Lupus Science and Medicine, 2019, 6, e000327.	1.1	11
49	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.5	12
50	Loss of an IgG plasma cell checkpoint in patients with lupus. Journal of Allergy and Clinical Immunology, 2019, 143, 1586-1597.	1.5	36
51	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	2.9	55
52	Patterns of ANA+ B cells for SLE patient stratification. JCI Insight, 2019, 4, .	2.3	25
53	Lupus community panel proposals for optimising clinical trials: 2018. Lupus Science and Medicine, 2018, 5, e000258.	1.1	62
54	Longâ€“Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2018, 70, 868-877.	2.9	63

#	ARTICLE	IF	CITATIONS
55	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	0.9	37
56	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	1.5	55
57	Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World Clinicians. <i>Arthritis Care and Research</i> , 2018, 70, 1058-1063.	1.5	13
58	Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder. <i>Arthritis and Rheumatology</i> , 2018, 70, 277-286.	2.9	45
59	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	1.5	21
60	TD-05â€¦Dynamic contrast enhanced MRI (DCE-MRI) demonstrates hippocampus permeability in SLE. , 2018, , .		0
61	AI-18â€¦The effect of belimumab on B cell selection in human SLE. , 2018, , .		1
62	CS-07â€¦Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
63	CT-03â€¦Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis. , 2018, , .		0
64	Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. <i>Arthritis Research and Therapy</i> , 2018, 20, 133.	1.6	30
65	Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. <i>Molecular Medicine</i> , 2018, 24, 24.	1.9	12
66	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
67	Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon- β monoclonal antibody, in SLE subjects without or with lupus nephritis. <i>Lupus Science and Medicine</i> , 2017, 4, e000226.	1.1	49
68	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 287.	1.6	1
69	Checkpoints for Autoreactive B Cells in the Peripheral Blood of Lupus Patients Assessed by Flow Cytometry. <i>Arthritis and Rheumatology</i> , 2016, 68, 2210-2220.	2.9	65
70	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	2.9	40
71	Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection. <i>Lupus Science and Medicine</i> , 2016, 3, e000159.	1.1	37
72	A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2174-2183.	2.9	105

#	ARTICLE	IF	CITATIONS
73	Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2016, 197, 2854-2863.	0.4	18
74	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	0.9	370
75	A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus. <i>Immunologic Research</i> , 2015, 63, 167-169.	1.3	15
76	Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D ₃ on the Interferon Signature in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 1848-1857.	2.9	73
77	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	2.9	98
78	Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2015, 2, e000074-e000074.	1.1	34
79	Remission in SLE: closing in on the target. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2103-2106.	0.5	19
80	Selective Impairment of Spatial Cognition Caused by Autoantibodies to the N-Methyl-d-Aspartate Receptor. <i>EBioMedicine</i> , 2015, 2, 755-764.	2.7	71
81	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.5	70
82	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.5	391
83	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
84	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.5	143
85	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
86	Differences in Regional Brain Activation Patterns Assessed by Functional Magnetic Resonance Imaging in Patients with Systemic Lupus Erythematosus Stratified by Disease Duration. <i>Molecular Medicine</i> , 2011, 17, 1349-1356.	1.9	39
87	Vitamin D and the Immune System. <i>Journal of Investigative Medicine</i> , 2011, 59, 881-886.	0.7	827
88	Glutamate Receptor Biology and its Clinical Significance in Neuropsychiatric Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 187-201.	0.8	42